deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04135495

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele

Sponsor: Eloxx Pharmaceuticals, Inc.

Conditions Cystic Fibrosis
Interventions ELX-02 Ivacaftor
Updated 16 times since 2019 Last updated: Nov 21, 2022 Started: Nov 25, 2019 Primary completion: Oct 3, 2022 Completion: Oct 3, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cystic Fibrosis, this trial is completed. The trial is conducted by Eloxx Pharmaceuticals, Inc. and has accumulated 16 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Dec 2022 · 9 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Mar 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  2. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  3. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  7. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  11. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eloxx Pharmaceuticals, Inc.
Data source: Eloxx Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations